NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer
NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer
Latest in lung cancer genomic testing
HER-Vaxx is safe and provides clinical benefit over standard of care chemo for patients with HER2-overexpressing gastric cancer
Zolbetuximab + mFOLFOX6 as 1L treatment shows significantly prolonged PFS and OS in CLDN18.2+/ HER2 mG/GEJ adenocarcinoma
Kinetics of postop circulating cell-free DNA and impact on MRD detection rates in resected stage I-III colorectal cancer
OPERA: Nonoperative modality (NOM) treatments of rectal cancer do not compromise the chance of cure
NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful survival benefit vs chemo for advanced ESCC
The placebo effect in oncology trials and the criteria for approving drugs
Breast-conserving therapy may be option for multiple breast lesions
Elacestrant shows improved PFS in ER-positive/HER2-negative mBC
ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL
Shorter time from leukapheresis to infusion of axi-cel corresponds to better CR and OS in r/r LBCL patients